Collegium Pharmaceutical, Inc. / Fundamentals
Income statement
- Net revenue
€606.61M - Cost of goods sold
€262.73M - Gross profit
€343.88M - SG&A expenses
€236.04M - R&D expenses
€0.00 - EBITDA
€297.49M - D&A
€181.41M - EBIT
€111.32M - Interest expenses
€70.61M - EBT
€45.47M - Tax expenses
€14.35M - Net income
€31.12M
Cash flow statement
- Net deferred tax
-€19.17M - Non-cash items
-€49.54M - Changes in working capital
€2.64M - Operating cash flow
€174.59M - Capex
€1.44M - Other investing cash flow
-€229.55M - Net investing cash flow
-€234.51M - Total cash dividends paid
€0.00 - Issuance of common stock
-€8.56M - Debt repayment
€85.90M - Other financing cash flow
-€14.00M - Net financing cash flow
€29.30M - Foreign exchange effects
€0.00 - Net change in cash
-€29.73M - Cash at end of period
€118.62M - Free cash flow
€176.03M
Balance sheet
- Cash and cash equivalents
€100.68M - Cash and short-term investments
€190.61M - Total receivables
€182.77M - Inventory
€32.73M - Other current assets
€65.11M - Total current assets
€471.22M - Property, plant & equipment
€15.59M - Goodwill
€126.93M - Intangible assets
€669.63M - Long-term investments
€0.00 - Other non-current assets
€4.20M - Total non-current assets
€895.26M - Total assets
€1.37B - Accounts payable
€9.34M - Short-term debt
€56.56M - Other current liabilities
€324.78M - Total current liabilities
€398.63M - Long-term debt
€654.82M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€105.21M - Total non-current liabilities
€768.61M - Total liabilities
€1.17B - Common stock
€34.32K - Retained earnings
-€128.36M - Other equity
€289.15K - Total equity
€199.23M - Total liabilities and shareholders' equity
€1.37B
Company information
- Market capitalization
€820.55M - Employees
357 - Enterprise Value
€1.70B
Company ratios
- Gross margin
-
56.7% Much better than peer group: -6,552.5% - EBITDA margin
-
49.0% Much worse than peer group: 1,074,964.1% - EBIT margin
-
18.4% Much worse than peer group: 1,011,850.9% - EBT margin
-
7.5% Much worse than peer group: 1,075,516.9% - Net margin
-
5.1% Much worse than peer group: 974,441.2% - ROE
-
15.6% Even with peer group: 16.6% - ROA
-
2.3% Much better than peer group: -23,883.6% - Asset turnover
-
44.4% Much worse than peer group: 6,728.6% - FCF margin
-
28.5% Much worse than peer group: 755,554.9% - FCF yield
21.1% - Efficiency ratio
51.0% - Net sales per employee
-
€1.70M - Net income per employee
-
€87.17K